http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-0049409-A2

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2f266dc1e88e0c0de895931dc504024d
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2500-00
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6854
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-9493
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-94
filingDate 2000-02-15-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9527e28969afed79dfe2ae8f693ceb34
publicationDate 2000-08-24-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber WO-0049409-A2
titleOfInvention ASSAY FOR THE IDENTIFICATION OF IgE ANTIBODY SUPPRESSORS
abstract The invention provides an IgE and antigen-specific screening assay for use in identifying agents which suppress the IgE mediated immune response to antigen. The assay is performed in vivo in Animals which hyper respond to antigen by producing exaggerated levels of IgE. The animals are sensitized to an antigen during a specific window of sensitivity which closes a day after the animal has been treated to produce the IgE hyper responsive phenotype. The screening assay is performed in the animals by treating them with a candidate IgE suppressor agent in conjunction with further immunization made after closure of the window of sensitivity defined by the invention. Positive results (indicating that the candidate agent has IgE suppressive activity) are obtained in the assay through measurement of a decline in antigen-specific IgE in the animal following its treatment with the candidate agent. The screening assay may also be utilized to measure other components of the immune response to antigen, including IgG1 and IgG2a antibody production.
priorityDate 1999-02-17-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9958663-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9961013-A2
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCQ6V115
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCO73860
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP19104
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID786492
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID128904227
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID18424374
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP01012
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP02879
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCE2RVI8
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID3958

Total number of triples: 28.